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Abstract
Background: Hepatitis B virus (HBV) infection correlated with the development of cirrhosis, liver failure and
hepatocellular carcinoma (HCC), poses a huge health burden on the global community. However, the
pathogenesis of chronic hepatitis B (CHB) remains unclear. Apolipoprotein A1 (ApoA1) mainly secreted by
hepatocytes, represents the major protein component of high-density lipoprotein. ApoA1 secretion may be
disrupted by HBV infection. In this study, we mainly investigated the molecular mechanism of ApoA1 down
regulated by HBV for revealing the pathogenesis of CHB.
Methods: ApoA1 expression in livers of CHB patients as well as healthy controls were performed by Real-time PCR
(RT-PCR) and Western blot. The serum ApoA1 levels were measured by Enzymed-linked immunosorbent assay (ELISA).
Expression of ApoA1 mRNA and protein levels were performed by RT-PCR and Western blot in human hepatoma
HepG2 cells and subline HepG2.2.15 cells. HBV expression construct, pHBV1.3 were transfected into HepG2, the
changes of ApoA1 mRNA and protein expression were detected by RT-PCR and Western blot. To further study the
mechanism of ApoA1 down regulation by HBV, 11 CpG islands in ApoA1 promotor were tested for DNA methylation
status by MSP. HepG2.2.15 cell lines were treated with DNA methyltransferase inhibitor 5-aza-deoxycytidine (5-aza-dC),
then, expression of ApoA1 mRNA and HBV particles in the supernatant, as well as ApoA1 protein levels were detected
by RT-PCR and Western blot. Secretion of HBsAg and HBeAg in HepG2 cells cotransfected with pApoA1 and pHBV1.3
constructs was tested by ELISA. Meanwhile, secretion of HBsAg and HBeAg in the supernatant were quantified by
ELISA in the HepG2.2.15 cells treated with 5-aza-dC plus ApoA1 siRNA.
Results: Expression of ApoA1 mRNA and protein levels, as well as serum ApoA1 levels in CHB patients were
decreased corresponding healthy controls in vivo. In addition, the expression of ApoA1 mRNA and protein levels
were down regulated in HepG2.2.15 cells correponding HepG2 cells, 11 CpG islands in ApoA1 promoter were tested
for methylation status by MSP in HepG2.2.15 cells compared to HepG2 cells, while two CpG islands were
found hypermethylated. Expression of ApoA1 mRNA and protein levels were increased in HepG2.2.15 cells treated
with DNA methyltransferase inhibitor 5-aza-dC. Furthermore, overexpression of ApoA1 can enhance HBV expression
in HepG2 cells while the inhibitory effect of 5-aza-dC on HBV expression was completely abolished by blocking
5-aza-dC-induced up-regulation of ApoA1 using RNAi.
Conclusions: Epigenetic silencing of ApoA1 gene expression by CpG island DNA hypermethylation induced by HBV
may contribute to the pathogenesis of CHB.
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Background
Around 3 billion people wordwide were infected with
Hepatitis B virus (HBV) which causes persistent live
diseases. Chronic hepatitis B (CHB) correlated with a
significant increased risk of cirrhosis, liver failure and
hepatocellular carcinoma (HCC), poses a huge health
burden on the global community [1–3]. However, the
pathogenesis of CHB remains unclear.
Apoliprotein A1 (ApoA1), as a major protein com-
ponent of high-density lipoprotein (HDL) is secreted
normally by live and intestine. It is well known that
ApoA1 and HDL show besides the cholesterol trans-
port from peripheral cells to the liver [4], also have
the important anti-inflammatory properties [4–6].
Moreover, Hyperlipidemia and Atherogenesis are often
accompanied by abnormal expression of ApoA1 and
HDL [7, 8].
In previous studies, plasma ApoA1 levels were appar-
ently decreased in CHB patients corresponding healthy
controls in vivo [9]. Similar results had shown the expres-
sion of ApoA1 was significantly decreased in hepatoma
HepG2.2.15 (integrated the HBV genome) compared to
HepG2 cells in vitro. Moreover, ApoA1 expression and
promoter activities were down-regulated by HBV in a
dose dependent manner [10]. HBV mRNAs and ApoA1
mRNA had shown a negative correlation in two hepatoma
cell lines [11]. Notably, our recent study showed HBx
interation led to an inpaired lipid-binding ability of ApoA1
while ApoA1 overexpression inversely promoted HBV
expression [12]. Taken together, ApoA1 was suppressed
by HBV at least partly due to trancriptional suppression.
However, the regulatory mechanism are almost unknown.
Given the importance of ApoA1 in the cholesterol trans-
port and HBV regulation [13], the aim of the present
study was to investigate the molecular mechanism of
ApoA1 suppression by HBV for revealing the patho-
genesis of CHB.
Patients and methods
Human specimens and serum samples
Liver sections from 200 CHB patients and 50 healthy
controls were collected for detection of ApoA1 protein
levels in liver. Serum samples were collected from 250
CHB patients and 50 healthy controls for detection of
circulating ApoA1 levels. CHB patients, defined as serum
HBsAg positivity for at least 6 months, may have exhibited
symptoms of hepatitis or abnormal hepatic function. All
the patients were hospitalized in West China Hospital,
Sichuan University for Infectious Diseases from January
2014 and December 2014 and provided the informed con-
sent in written form. The study protocols were approved




DNA methyltransferase inhibitor 5-aza-deoxycytidine
(5-aza-dC) (A3656) was purchased from Sigama; ApoA1
ELISA detection kit (ab108804) was purchased from
Abcam. Superscript™ RT reagent kit (DRR037A, Takara
BioInc., Shiga, Japan); ApoA1 specific siRNA and non-
specific control (sc-63361, sc-37007, Santa Cruz Biotech-
nology); the rabbit anti-human ApoA1 (sc-30089, Santa
Cruz Biotechnology); the mouse anti-human actin and the
horseradish peroxidase-conjugated secondary antibodies
(Zhongshan Goldenbridge Biotechnology, China); and the
ECL-Plus chemiluminescence system (Applygen Technolo-
gies, Beijing, China).
Cell culture and constructs
Human hepatocellular carcinoma HepG2 and HepG2.2.15
cell lines were obtained from the ATCC (Rockville, MD),
HepG2.2.15 with abilities to produce HBV virus stably is
derived from HepG2 cell lines [14]. HBV replication plas-
mid pHBV1.3, containing 1.3 copies of the HBV genome
(D genotype), pCDNA3.1-ApoA1 (pApoA1), containing
coding sequence of ApoA1 were both kept in lab [2, 12].
Immunoblot analysis
An equal amount of protein from liver sections of CHB
patients as well as healthy controls were separated in
a 10 % SDS–polyacrylamide gel and probed with an
anti-ApoA1 and an anti-human actin antibody. The
bound antibodies were visualized with appropriate HRP-
conjugated secondary antibodies using an ECL detection
kit.
RNA, DNA extraction and real-time PCR
Total RNA was extracted from HepG2.2.15 cells treated
with 5-aza-dC or negative control by Trizol Reagent (Invi-
trogen), as recommended by the manufacturer. GAPDH
was used as an internal standard for the quantification of
real-time PCR (RT-PCR), the primers used to detect
ApoA1 and GAPDH have been described in previous
studies [2, 15].
Supernatant in HepG2.2.15 cells was harvested at 48 h
after treatment with 5 μM 5-aza-dC or negative control
for detection of HBV particles [16]. HBV particles were
quantitatively measured by RT-PCR according to the
manufacturer's instructions of HBV PCR assay II kit
(Tiangen. Co. Ltd.).
Enzymed-linked immunosorbent assay (ELISA)
ELISA tests for detection of ApoA1 expression in serum
of CHB patients and healthy controls were performed as
recommended by the manufacturer.
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Methylmion Specific PCR (MSP)
The methylation levels of ApoA1 promoter were detected
by MSP in Shanghai Integrated Biotech Solutions Co.,
Ltd.
Statistical analysis
Each experiment was performed in triplicate, and all
experiments were repeated three times. The results are
presented as the mean ± standard deviation. Using Stu-
dent’s t-test for comparison between groups, *p value
<0.05 and **p < 0.01 were considered as a significant
difference.
Results
Expression of ApoA1 mRNA and protein levels was
significantly decreased in CHB patients
Although ApoA1 expression has been shown to be specif-
ically suppressed in CHB patients corresponding healthy
controls [1], the evidences remain insufficient enough. To
highlight this question, we first detected plasma ApoA1
expression from 250 CHB patients and 50 healthy controls
by ELISA. As can be seen in Fig. 1a, plasma ApoA1 ex-
pression was significantly decreased by 39.9 % in CHB
patients corresponding healthy controls. To further deter-
mine the changes of ApoA1 expression in lives of CHB
patients, we detected ApoA1 protein and mRNA levels by
Western blot and RT-PCR, respectively. As demonstrated
in Fig. 1b and c, ApoA1 protein and mRNA levels were
decreased dramatically in CHB patients compared with
healthy controls.
HBV induced down-regulation of ApoA1
Next, we explored whether the expression of ApoA1
was affected by HBV in hepatoma cells, HepG2 and
HepG2.2.15 cells were selected for testing whether ApoA1
was subject to regulation by HBV because HepG2.2.15
cells stably produce HBV virus and derived from HepG2
cell lines. As can be seen in Fig. 2a, ApoA1 mRNA levels
were significantly decreased by 50.6 % in HepG2.2.15 cor-
responding HepG2 cells. Moreover, ApoA1 protein levels
detected by Western blot were dramatically reduced
(Fig. 2b). To highlight whether the suppression of ApoA1
due to HBV expression, HepG2 cells were transfected with
2 μg pHBV1.3 plasmid or 2 μg pCDNA3.1 as control,
expression of ApoA1 mRNA and protein levels was appar-
ently decreased at 48 h after pHBV1.3 transfection. These
results suggested HBV can inhibit ApoA1 mRNA and pro-
tein levels in hepatoma cells.
ApoA1 expression was suppressed mainly through ApoA1
promotor hypermethylation by HBV
According to previous studies, ApoA1 expression and
promoter activities were both inhibited by HBV [1]. To
further demonstrate the underlying molecular mechanism,
we surveyed the CpG island hypermethylation status in
ApoA1 promotor by MSP in HepG2.2.15 corresponding
HepG2 cells, the data showed that there were 11 CpG
islands found in ApoA1 promotor while two CpG islands
were hypermethylated. The position of 5 CpG islands
including two hypermethylation status (sites 4 and sites 5)
were shown in Fig. 3a (other data not shown), the methy-
lation results of the 5 CpG islands were shown in Fig. 3b.
To illustrate whether ApoA1 expression was affected by
ApoA1 promotor hypermethylation, HepG2.2.15 cells
were treated with 5 μM DNA methyltransferase inhibitor
5-aza-dC for 48 h. We chose to use 5 μM 5-aza-dC for
the experiment because this concentration has been veri-
fied efficiently [16]. Then, ApoA1 mRNA and protein
levels were detected by RT-PCR and Western blot respect-
ively. As shown in Fig. 3c, ApoA1 mRNA levels with 5-
aza-dC treatment were apparently elevated by 53.5 %
corresponding negative control. Furthermore, ApoA1
protein levels were also apparently increased (Fig. 3d).
Moreover, secretion of HBsAg and HBV paticles in the
Fig. 1 ApoA1 expression was significantly decreased in CHB patients. a plasma ApoA1 levels were performed by ELISA in 250 CHB patients
corresponding 50 healthy control. b and c ApoA1 protein levels in live tissue sections were detected by Western blot wherase ApoA1 mRNA
levels from 200 CHB patients and 50 healthy controls were analyzed by RT-PCR. Results of the Real-time PCR were normalized to an endogenous
control GAPDH. The ApoA1 mRNA levels in healthy controls were arbitrarily set as 1.0. Error bars are means ± standard deviation (SD). Data are
presented as the mean ± SD from three independent experiments. *p < 0.05 and **P < 0.01 compared with mock
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supernatant of HepG2.2.15 cells treated with 5 μM 5-
aza-dC were apparently decreased by 26.8 % and 60.4 %
respectivly (Fig. 3e and f ). Our results demonstrated
suppression of ApoA1 expression may be due to its
promotor hypermethylation by HBV.
Decreased HBV expression in HepG2.2.15 cells with 5-aza-dC
treatment via up-regulation of ApoA1 expression
To confirm the functional role of ApoA1 in the life cycle
of HBV, HepG2 cells were cotransfected with 1 μg
pApoA1 plasmid and 1 μg pHBV1.3. Secretion of HBsAg
and HBeAg were analyzed by ELISA at 48 h after trans-
fection (Fig. 4a). Results showed that over expression of
ApoA1 remarkably reduced the secretion of HBsAg by
30 % and HBeAg by 35.4 %. In conclusion, our results
have shown 5-aza-dC treatment in HepG2.2.15 cells
increased ApoA1 expression and decreased HBV pro-
duction while ApoA1 overexpression suppressed HBV
expression in HepG2 cells (Fig. 3e-f and Fig. 4a). To
explore whether decreased HBV expression in 5-aza-dC
treated HepG2.2.15 cells via up-regulation of ApoA1
levels, HepG2.2.15 cells were treated with ApoA1
siRNA. As indicated in Fig. 4b, analysis of HBsAg and
HBeAg in the supernatant by ELISA revealed approxi-
mately equal amount of HBsAg and HBeAg between 5-
aza-dC plus ApoA1 siRNA treated cells and negative
control. Notably, the inhibitory effect of 5-aza-dC on
HBV expression was completely abolished by blocking 5-
aza-dC-induced up-regulation of ApoA1 mRNA using
RNAi (P > 0.05).
Discussion
Most cases of HCC are HBV-related in china. Abnormal
liver functions are correlated with altered liver protein
profiles, which may play important roles in the develop-
ment and prognosis of liver injury [17]. The protein
expression profiles have been detected with CHB and
HBV-related cirrhosis patients [9]. ApoA1 was paid
more attention because of the altered expression and
migration pattern. However, contradictory results about
the levels of plasma proteins in various liver diseases
were obtained. Earlier studies reported that plasma pro-
teins such as haptoglobin, α1-antitrypsin, and ApoA1
were suppressed in CHB patients while other studies
showed different results [9, 18]. To further confirm the
variation trends of ApoA1, our results suggested plasma
ApoA1 as well as ApoA1 expression in CHB patients
were decreased corresponding healthy controls in vivo.
Moreover, expression of ApoA1 mRNA and protein
levels was inhibited by HBV in the dose dependent man-
ner in hepatoma cells.
Fig. 2 Suppression of ApoA1 expression by HBV. a and b ApoA1 mRNA and protein levels were detected by RT-PCR and Western blot in HepG2.2.15
corresponding HepG2 cell lines. c and d HepG2 cells were transfected with 2 μg pHBV1.3 plasmid or 2 μg pCDNA3.1 as control, ApoA1 mRNA
and protein levels were detected at 48 h after transfection. Data are presented as the mean ± SD from three independent experiments. *p < 0.05 and
**P < 0.01 compared with mock
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The molecular mechanism of ApoA1 down-regulated
by HBV was further explored. In our previous study,
ApoA1 was confirmed as a HBx-interacting protein and
its lipid-binding ability was impaired by HBx [12]. Fur-
thermore, the luciferase activities of ApoA1 promotor
was also down regulated by HBV in hepatoma cells [1].
However, the signal pathway of the regulation of HBV
on ApoA1 expression and its exact mechanism still
waits further investigation. We found 11 CpG islands in
ApoA1 promotor and surveyed the CpG island hyper-
methylation status by MSP in HepG2.2.15 cells corre-
sponding HepG2 cells. Two CpG island hypermethylation
status were detected in ApoA1 promotor in HepG2.2.15
cells (Fig. 3b). It is well known that DNA methylation is
governed by the interaction of DNA methyltransferases
(DNMT) whose activities are inhibited by DNA methyl-
transferases inhibitor 5-aza-dC [19, 20]. A recent study
demonstrated the mRNA levels of DNMT1, DNMT3A
and DNMT3B in HBV-associated tissues were signifi-
cantly higher than in the non-HBV-associated tissues,
which may lead to hypermethylation/inactivation of p16
[21]. To determine whether the CpG island DNA hyper-
methylation of ApoA1 might be related with HBV infec-
tion, HepG2 cells, transfected with 2 μg pHBV1.3, were
treated with DNA methyltransferase inhibitor 5-aza-dC,
the inhibitory effect of HBV on ApoA1 expression was
completely abolished, indicating suppression of ApoA1
by HBV may be through hypermethylating ApoA1 pro-
motor via up-regulation of DNMT1, DNMT3A and
DNMT3B [21, 22].
Fig. 3 ApoA1 expression was suppressed by DNA methyltransferase inhibitor 5-aza-dC. a and b 5 CpG islands including two methylation CpG
status in ApoA1 promotor were listed (a), the detection results of the 5 CpG islands methylation status were shown (b). HepG2.2.15 cells treated
with 5 μM 5-aza-dC 48 h, ApoA1 mRNA and protein levels were detected by RT-PCR and Western blot respectively (c and d). Secretion of HBsAg
and HBV particles in the supernatant were detected by ELISA and RT- PCR respectivly (e and f). Data are presented as the mean ± SD from three
independent experiments. *p < 0.05 and **P < 0.01 compared with mock
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To further confirm the suppressed expression of HBV
induced by 5-aza-dC due to up-regulation of ApoA1
mRNA and protein levels, we found that decreased HBV
expression was completely abolished by ApoA1 knock-
down (Fig. 4b). Furthermore, secretion of HBsAg and
HBeAg was inhibited by ApoA1 overexpression, indicat-
ing ApoA1 inversly enhanced HBV expression, which
was in line with our previous study [12]. The potential
mechanism was that ApoA1 suppressed HBV expression
via inhibiting cellular cholesterol levels required for
HBV infection and escape from host cellular membrane.
Conclusions
In conclusion, our current study herein explored the
mechanism of ApoA1 down-regulated by HBV whereas
suppressed ApoA1 expression could further promote
HBV expression, which contributed to reveal the patho-
genesis of CHB. In addition, the overexpression of ApoA1
would inhibit HBV expression, providing the theoretical
basis for clinical diagnosis and treatment of CHB.
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